CRIS Current Research Information System

PILERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.927
AS - Asia 17.218
EU - Europa 14.571
SA - Sud America 1.177
AF - Africa 1.002
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 24
Totale 56.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.669
SG - Singapore 4.686
CN - Cina 4.643
GB - Regno Unito 4.206
VN - Vietnam 4.184
DE - Germania 1.925
IT - Italia 1.837
SE - Svezia 1.600
HK - Hong Kong 1.092
FR - Francia 1.070
UA - Ucraina 1.032
IN - India 987
RU - Federazione Russa 902
BR - Brasile 856
IE - Irlanda 498
ZA - Sudafrica 418
JP - Giappone 332
EE - Estonia 300
KR - Corea 288
CH - Svizzera 234
BD - Bangladesh 207
NL - Olanda 200
FI - Finlandia 197
CI - Costa d'Avorio 194
AR - Argentina 141
CA - Canada 141
TG - Togo 140
SC - Seychelles 87
PH - Filippine 86
JO - Giordania 82
HR - Croazia 73
BE - Belgio 72
ID - Indonesia 72
TR - Turchia 70
TH - Thailandia 69
GR - Grecia 68
BG - Bulgaria 65
MX - Messico 65
IQ - Iraq 60
IR - Iran 57
AT - Austria 56
PK - Pakistan 52
TW - Taiwan 49
PL - Polonia 47
LB - Libano 46
NG - Nigeria 46
EC - Ecuador 44
ES - Italia 42
CL - Cile 37
SA - Arabia Saudita 31
UZ - Uzbekistan 31
CO - Colombia 30
LU - Lussemburgo 30
LT - Lituania 22
EG - Egitto 20
MY - Malesia 20
TN - Tunisia 20
AU - Australia 18
PY - Paraguay 18
VE - Venezuela 18
EU - Europa 17
MA - Marocco 14
PE - Perù 14
RO - Romania 14
UY - Uruguay 13
DZ - Algeria 12
KE - Kenya 12
AE - Emirati Arabi Uniti 11
CZ - Repubblica Ceca 11
ET - Etiopia 11
JM - Giamaica 11
AL - Albania 10
DO - Repubblica Dominicana 10
NZ - Nuova Zelanda 10
PT - Portogallo 10
IL - Israele 9
OM - Oman 9
HU - Ungheria 8
CR - Costa Rica 7
DK - Danimarca 7
SK - Slovacchia (Repubblica Slovacca) 7
BO - Bolivia 6
KG - Kirghizistan 6
RS - Serbia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
NP - Nepal 5
AO - Angola 4
AZ - Azerbaigian 4
GE - Georgia 4
HN - Honduras 4
KZ - Kazakistan 4
PS - Palestinian Territory 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
BA - Bosnia-Erzegovina 3
GH - Ghana 3
GT - Guatemala 3
IS - Islanda 3
KH - Cambogia 3
KW - Kuwait 3
Totale 56.887
Salva come PNG Salva come JPEG
Città #
Southend 3.699
Singapore 3.083
Fairfield 2.741
Ashburn 2.034
Woodbridge 1.379
Chandler 1.266
Houston 1.261
Seattle 1.206
Wilmington 1.201
San Jose 1.108
Hong Kong 1.031
Cambridge 983
Princeton 882
Ho Chi Minh City 825
Ann Arbor 813
Dong Ket 694
Hanoi 684
Jacksonville 639
Hefei 627
Santa Clara 584
Boardman 526
Dublin 496
Beijing 488
Lauterbourg 425
Nanjing 420
Westminster 382
Padova 374
Los Angeles 318
Tokyo 297
Bologna 247
Seoul 240
New York 236
Berlin 227
Buffalo 211
Saint Petersburg 204
Jinan 196
Abidjan 193
Bern 192
Milan 190
Council Bluffs 178
Helsinki 171
Shenyang 169
Mülheim 146
Nanchang 144
San Diego 143
Lomé 139
Hebei 133
Changsha 121
Dallas 120
Haiphong 114
Tianjin 114
Bremen 112
Da Nang 108
São Paulo 101
Frankfurt am Main 98
Guangzhou 97
Redondo Beach 91
Jiaxing 88
Zhengzhou 86
Chicago 84
Amman 81
Shanghai 80
Hangzhou 79
Phoenix 78
Medford 71
Mahé 69
The Dalles 67
Brussels 63
Sofia 62
Bengaluru 60
Dearborn 60
Turin 60
Ningbo 57
Hyderabad 55
Munich 55
Norwalk 55
Rome 55
Taizhou 55
Redwood City 54
Falls Church 50
Haikou 49
Olalla 49
San Venanzo 49
Yubileyny 49
Toronto 48
London 47
Taiyuan 47
Des Moines 46
Johannesburg 46
Abeokuta 42
Montreal 42
Verona 42
Redmond 40
Hải Dương 39
Nuremberg 39
San Francisco 39
Can Tho 37
Biên Hòa 34
Lanzhou 34
Wuhan 34
Totale 37.277
Salva come PNG Salva come JPEG
Nome #
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 327
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 290
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 285
Biology and treatment of follicular lymphoma. 282
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 272
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 269
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 258
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 258
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 256
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 256
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 253
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 252
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 252
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 250
B-cells and mixed cryoglobulinemia. 247
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 245
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 243
B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. 237
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
IFI16 expression is related to selected transcription factors during B-cell differentiation 231
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 228
T-Cell Lymphomas in South America and Europe 227
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 223
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 222
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 222
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 221
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. 220
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 220
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 218
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 215
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 212
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 212
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 210
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 210
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 209
Expression of CD52 in peripheral T-cell lymphoma. 208
Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change 208
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 205
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 203
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 200
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 200
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 199
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 199
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 197
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 196
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 196
CD30 expression in peripheral T-cell lymphomas 195
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 194
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 194
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 192
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 192
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 191
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. 190
Histopathology of B-cell chronic lymphocytic leukemia. 190
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas 189
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 188
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 188
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 186
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 186
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 186
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 186
Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. 185
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 185
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 183
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 183
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 183
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 183
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 183
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 181
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 181
Anaplastic Large Cell Lymphoma: a critical reappraisal 180
The emerging role of GSK-3β in the pathobiology of classical Hodgkin lymphoma 180
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma 179
Peripheral T-cell lymphoma - Not otherwise specified. 179
BCL10 down-regulation in peripheral T-cell lymphomas. 179
Pathobiology of hodgkin lymphoma. 179
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 178
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 178
Small bowel obstruction caused by a large B-cell lymphoma in a patient with multicentric Castleman’s disease: an unusual occurrence 178
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 178
Enteropathy-associated T-cell lymphoma. 177
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma 176
Aberrant promoter methylation of multiple genes thoughout the clinico-pathologic spectrum of B-cell neoplastia. 176
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary - Neoplasia a cellule dendritiche plasmocitoidi blastiche: il santuario cutaneo 175
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 175
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 173
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 173
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 172
Molecular profiling of aggressive lymphomas 172
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. 171
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 170
Pathobiology of anaplastic large cell lymphoma. 170
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 170
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 169
WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. 169
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 168
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 168
Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. 167
A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. 166
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 166
Totale 20.379
Salva come PNG Salva come JPEG
Categoria #
all - tutte 158.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 158.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.557 0 0 0 0 0 0 0 0 0 0 0 1.557
2021/20226.593 706 232 540 573 677 381 142 449 247 394 1.258 994
2022/20236.393 847 864 353 789 458 472 221 332 1.011 174 504 368
2023/20241.590 89 290 108 174 142 290 109 94 48 128 54 64
2024/20256.621 217 1.297 583 463 1.044 373 562 158 71 330 251 1.272
2025/202615.882 1.043 1.619 1.650 1.322 1.853 982 1.366 733 3.026 1.172 611 505
Totale 57.746